医学
卡铂
贝伐单抗
内科学
肿瘤科
彭布罗利珠单抗
人口
放化疗
培美曲塞
化疗
实体瘤疗效评价标准
癌症
外科
顺铂
临床研究阶段
免疫疗法
环境卫生
作者
Krishnansu S. Tewari,Nicoletta Colombo,Bradley J. Monk,Coraline Dubot,M. Valeria Cáceres,Kosei Hasegawa,Ronnie Shapira‐Frommer,Pamela Salman,Eduardo Yáñez,Mahmut Gümüş,Mivael Olivera,Vanessa Samouëlian,Vincent Castonguay,Alexander Arkhipov,Cumhur Tekin,Kan Li,Sarper Toker,Stephen J. O’Keefe,Domenica Lorusso
出处
期刊：JAMA Oncology
[American Medical Association]
日期：2023-12-14
卷期号：10 (2): 185-185
被引量：30
标识
DOI：10.1001/jamaoncol.2023.5410
摘要
The KEYNOTE-826 randomized clinical trial showed statistically significant and clinically meaningful survival benefits with the addition of pembrolizumab to chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer. Treatment effects in patient subgroups of the study population are unknown.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
浮游
asd_1
不想干活
核桃
XCL
SOL
紧张的惜梦
MchemG
GingerF
Dean
Virtual
兔兔兔
iNk
丁浩伦
null
8R60d8
馆长
斯坦933
敬老院N号
vizi
皖公网安备34019202002308
